Nasdaq · Healthcare

Intellia Therapeutics, Inc. (NTLA)

As-reported financials and recent SEC filings for Intellia Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$67.7M

Net income

$-412.7M

Net margin

—

Diluted EPS

$-3.81

ROE

-61.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$67.7M	$57.9M	$36.3M	$52.1M	$33.1M
Gross profit	—	—	—	—	—
Operating income	$-441.0M	$-534.3M	$-515.3M	$-458.2M	$-267.9M
Net income	$-412.7M	$-519.0M	$-481.2M	$-474.2M	$-267.9M
Diluted EPS	$-3.81	$-5.25	$-5.42	$-6.16	$-3.78

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-06

42026-07-06

1442026-07-02

8-K2026-06-15

42026-06-10

42026-06-10

42026-06-10

42026-06-10

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on NTLA

Search Intellia Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.